12 Peptides Could Return to Legal Compounding — FDA Sets Review Timeline

The regulatory picture for peptides in the United States is shifting. The FDA has announced that its Pharmacy Compounding Advisory Committee will hold two separate meetings — one in July 2026 and another by February 2027 — to evaluate whether twelve specific peptides should be permitted for use in compounded medications. If approved, licensed compounding pharmacies would be able to legally prepare these peptides for patients under physician supervision.

This is a significant development for anyone following the peptide space, and it's worth understanding what it actually means, how we got here, and which peptides are on the table.

Some Background: The 2023 Reclassification

In 2023, the FDA moved a group of peptides into what's called Category 2 — a classification that effectively made them ineligible for compounding at licensed pharmacies. Category 2 substances are those for which the FDA has determined there are safety concerns or insufficient evidence of benefit to justify compounding. The move drew criticism from practitioners and patients who had been accessing these peptides through compounding pharmacies for years.

The situation drew renewed public attention earlier this year when Department of Health and Human Services Secretary Robert F. Kennedy Jr. spoke at length about peptides during a public appearance. Kennedy described himself as a supporter of peptide therapies and argued that the 2023 reclassification was improper — claiming that FDA policy requires safety concerns to justify a Category 2 designation, and that such concerns were not adequately demonstrated for these compounds. He also pointed to an unintended consequence: following the compounding ban, some patients turned to unregulated sources, resulting in products of questionable purity and dosing accuracy.

The FDA's announcement of these advisory committee meetings appears to represent a formal response to that ongoing debate.

What Is a Compounding Pharmacy?

Compounding pharmacies prepare customized medications for individual patients — adjusting doses, removing allergens, changing the delivery form, or providing drugs that aren't commercially available. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies can prepare medications using substances on an approved "bulks list" without those substances needing to have gone through the full FDA drug approval process. That bulks list is what's being discussed here.

Being added to the 503A bulks list doesn't make a peptide an FDA-approved drug. It means that licensed pharmacies can legally prepare it with a valid prescription, under professional oversight, with quality controls in place. For patients, it means access through a regulated channel rather than through research chemical suppliers.

The July 2026 Meeting: Seven Peptides Under Review

The first advisory committee session is scheduled for July 23–24, 2026. The FDA has indicated it will review seven peptides at this meeting:

• BPC-157 (free base and acetate) — being considered for ulcerative colitis. One of the most widely discussed healing peptides in the research community, with an extensive animal literature on gut repair and tissue healing.
• KPV (free base and acetate) — a tripeptide fragment of alpha-MSH being reviewed for wound healing and inflammatory conditions.
• TB-500 (free base and acetate) — under consideration for wound healing. A synthetic fragment of thymosin beta-4, widely used in sports medicine contexts for tissue repair.
• MOTS-C (free base and acetate) — being evaluated for obesity and osteoporosis. A mitochondria-derived peptide with emerging research around metabolic regulation.
• Emideltide (free base and acetate) — being reviewed for opioid withdrawal, chronic insomnia, and narcolepsy.
• Semax (free base and acetate) — under consideration for cerebral ischemia and trigeminal neuralgia. Already an approved prescription medication in Russia with a long clinical track record.
• Epitalon (free base and acetate) — being reviewed for insomnia. A tetrapeptide with decades of research originating from Russian gerontology, primarily studied for sleep regulation and anti-aging effects.

The FDA has opened a public comment docket (FDA-2025-N-6895) for this meeting. Comments submitted before July 9, 2026 will be provided to the committee ahead of their deliberations. The docket closes July 22, 2026.

The February 2027 Meeting: Five More Peptides

A second session will take place before the end of February 2027, covering five additional peptides:

• Cathelicidin (LL-37) — an antimicrobial peptide produced naturally by the human immune system, studied for infection resistance and wound healing.
• GHK-Cu — a copper-binding tripeptide with a broad range of studied effects including skin repair, anti-inflammatory activity, and tissue regeneration.
• Dihexa — a peptide studied for cognitive enhancement and neuroprotection, with early research suggesting strong effects on memory and synaptic function.
• Melanotan II — a melanocortin receptor agonist originally developed as a tanning peptide, with applications also studied in sexual dysfunction. Related to the FDA-approved drug bremelanotide (PT-141).
• Mechano Growth Factor (PEG-MGF) — a splice variant of IGF-1 involved in muscle repair and regeneration, often discussed in recovery and sports medicine contexts.

No public comment docket has been announced for the February 2027 meeting yet.

What the Committee Actually Decides

The Pharmacy Compounding Advisory Committee is an expert panel that advises the FDA — it does not make binding decisions. The committee reviews the available evidence on a substance's safety, clinical utility, and need, and then makes a recommendation. The FDA considers those recommendations but is not obligated to follow them.

For each peptide, the committee will weigh factors like: Is there evidence of clinical benefit for the proposed indication? Are there safety concerns? Is there a medical need that isn't being met by currently available approved drugs? Would compounding serve patient populations that can't access or tolerate existing options?

The process is slow and outcomes are not guaranteed. Some substances reviewed in previous cycles were added to the bulks list; others were not. But the scheduling of these meetings is a meaningful step — it signals that these peptides are being formally reconsidered rather than left in regulatory limbo.

What This Means in Practice

If any of these peptides are added to the 503A bulks list, patients would be able to obtain them through licensed compounding pharmacies with a prescription, prepared under quality-controlled conditions. This is materially different from the current situation for most of these peptides, where access through unregulated research chemical suppliers carries real uncertainty about purity and dosing.

For practitioners who have been using these peptides off-label, a formal compounding pathway would provide clearer legal footing and supply chain accountability. For patients, it would mean access to professionally prepared products rather than self-sourced compounds.

It would not make these peptides FDA-approved drugs. That requires a full clinical trial program, which most peptides in this category have never completed. But it would create a structured, regulated middle ground between full approval and unregulated research chemical status.

The Broader Context

This announcement is part of a broader regulatory shift in how US authorities are approaching peptides. The GLP-1 agonists — semaglutide and tirzepatide — demonstrated that peptide drugs can achieve unprecedented clinical results and massive commercial scale. That success has increased institutional attention to the entire peptide category.

At the same time, the compounding industry has been central to patient access for many of these compounds, particularly during the semaglutide shortage period when the FDA temporarily permitted compounding of FDA-approved GLP-1 drugs. The regulatory machinery around compounding is being tested and refined in real time.

The July 2026 advisory meetings will be worth watching closely. We'll update this post as decisions are made.

Source: FDA Federal Register Notice — Pharmacy Compounding Advisory Committee Meeting, Docket FDA-2025-N-6895